Diamyd Medical has appointed FNCA Sweden AB as Certified Adviser

Diamyd Medical AB changes the Certified Adviser at Nasdaq Stockholm First North. FNCA Sweden AB (www.fnca.se) begins its commitment as of December 2, 2016. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the